← boardnext 2028-04
SMMT
Summit Therapeuticsdistress 3/10 · well-funded / low risk$14.96+1%today-49% from 52w high
Lead: Non-Small Cell Lung Cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$599M
Runway
1.6 yrs
Shares 1y
+5%
Price & events
-13.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.5%
1D
+8.7%
1W
+5.0%
1M
-32.8%
3M
-9.3%
6M
-46.6%
1Y
+48.3%
2Y
+87.0%
5Y
+189.4%
All
Overview
- Market Cap
- $11.61B
- Volume
- 200.64K
- 52 Week Range
- $13.05 – $29.32
- Total Shares
- 776.16M
- Float Shares
- 130.71M
- Short %
- 29.55%
- % Held by Insiders
- 83.14%
- % Held by Institutions
- 15.84%
- RVOL
- 0.04x
- Beta
- -1.26
Pipeline stages · 1 programs
Ivonescimab Injection, Pembrolizumab Injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-04 Estimated 50% readout ~2028-06-15 | Phase 3 | Ivonescimab Injection, Pembrolizumab Injection | Non-Small Cell Lung Cancer | — | recruiting |
| 2028-05-31 Estimated 50% readout ~2028-08-14 | Phase 3 | Ivonescimab Injection, Bevacizumab Injection | Metastatic Colorectal Cancer (CRC) | — | recruiting |
| 2028-12-31 Estimated 50% readout ~2029-03-16 | Phase 3 | Ivonescimab Injection, Pembrolizumab Injection | Non-Small Cell Lung Cancer | — | recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 10
- November 14, 2026Confirmed 100%PDUFAPDUFAivonescimab · Prescription Drug User Fee Act goal action dateSEC 8-K
- 2026-07-23earningsEarningsEarnings releaseyahoo
- 2026-06-10withdrawalWithdrew previously announced proposed underwritten public offering of securities due to market conditions.SEC 8-K
- June 1, 2026 at 7:00am ETconferencedata presentationsecondaryPhase 2/3ivonescimab · Conference call discussing ivonescimab data from AK112-206 and HARMONi-6 trials.SEC 8-K
- 2026-01-12partnershipivonescimab, risvutatug rezetecan · Clinical trial collaboration with GSK to evaluate ivonescimab in combination with GSK's B7-H3 ADC across multiple solid tumors including SCLCSEC 8-K
- January 12, 2026conferencedata presentationsecondaryPresented at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- January 12, 2026regulatory submissionFiled (NDA/BLA)ivonescimab · BLA submitted to FDA for ivonescimab in combination with chemotherapySEC 8-K
- fourth quarter of 2025regulatory submissionFiled (NDA/BLA)ivonescimab · Plan to submit BLA for ivonescimab plus chemotherapy based on HARMONi trial results.SEC 8-K
- October 17, 2025trial initiationsecondaryPhase 3ivonescimab · Initiation of HARMONi-GI3 global Phase III study in first-line colorectal cancer.SEC 8-K
- 8:00am ET on September 8, 2025conferencedata presentationsecondaryPhase 3ivonescimab · Company conference call to discuss ivonescimab data from HARMONi.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $29 (+91% upside) · 13 analysts
- 2026-05-22BernsteinUnderperform
- 2026-05-22HC Wainwright & Co.Buy → Neutral
- 2026-05-04HC Wainwright & Co.Buy
- 2026-05-01Piper SandlerNeutral
- 2026-04-08StifelBuy
- 2026-03-16JefferiesBuy → Hold
Competitors — Non-Small Cell Lung Cancer
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- PFEPFIZER INC$142.2B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- RVMDRevolution Medicines, Inc.$40.3B · D1
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- MAIAMAIA Biotechnology, Inc.$78M · D5
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-23H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics - Investing.com
- 2026-07-23SMMT Reiterated by HC Wainwright & Co. -- Rating Maintained at Neutral - GuruFocus
- 2026-07-23Summit Therapeutics (SMMT) Updates on Ivonescimab Lung Cancer Tr - GuruFocus
- 2026-07-22Summit updates survival data for Akeso-partnered lung cancer drug - MSN
- 2026-07-22Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data - Seeking Alpha
- 2026-07-22Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug - Benzinga
- 2026-07-22Summit Therapeutics (SMMT) Reports Positive Updates from HARMONi Clinical Trial - GuruFocus
- 2026-07-22Summit Therapeutics shares advance after updated Phase III cancer trial results (NASDAQ:SMMT) - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.